drugset / Trial / NCT05346302
Persistent Readiness Through Early Prediction Immunization Study
Phase 0
Completed
249 enrolled
Texas A&M University
Philips Healthcare · collabUS Department of Defense - Defense Threat Reduction Agency · collab
RandomizedParallel-groupDouble-blindOther
Summary
This study will enroll volunteers in an open-format (outside hospital) setting, to complete novel data collection/analysis of biomarkers, facial images, and audio-recording to establish an optimal set of parameters to predict emergent cases of infection via an early warning score, along with actionable personalized information.
Timeline
- Start
- 2022-02-08
- Primary completion
- 2022-12-21
- Completion
- 2022-12-21
Publications
- Schrader SE, Hansen JR, O'Bryon I, Ruebush LE, Deutz NE, Wahl JH, Deatherage Kaiser BL. Volatile organic compound and proteomics data from the same exhaled breath condensate sample. J Breath Res. 2025 Aug 4;19(4). doi: 10.1088/1752-7163/adf34d.
- Wang C, Damiano RJ, Ruebush LE, Engelen MPKJ, Mariani S, Liu L, Silva I, Borhani S, Cote GL, Conroy B, McFarlane D, Deutz NEP. A randomized, triple-blinded, placebo-controlled clinical trial evaluating immune responses of Typhim Vi and PPSV23 vaccines in healthy adults: The PREP study. Vaccine. 2024 Dec 2;42(26):126292. doi: 10.1016/j.vaccine.2024.126292. Epub 2024 Sep 7.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pneumovax 23 | Vaccine | 0.5 ml | Intramuscular |
| Comparator | Typhim Vi | Vaccine | 0.5 ml | Intramuscular |